These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27712113)

  • 1. Palonosetron and hydroxyzine pre-treatment reduces the objective signs of experimentally-induced acute opioid withdrawal in humans: a double-blinded, randomized, placebo-controlled crossover study.
    Erlendson MJ; D'Arcy N; Encisco EM; Yu JJ; Rincon-Cruz L; Peltz G; Clark JD; Chu LF
    Am J Drug Alcohol Abuse; 2017 Jan; 43(1):78-86. PubMed ID: 27712113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ondansetron Does Not Reduce Withdrawal in Patients With Physical Dependence on Chronic Opioid Therapy.
    Chu LF; Sun J; Clemenson A; Erlendson MJ; Rico T; Cornell E; Obasi H; Sayyid ZN; Encisco EM; Yu J; Gamble JG; Carroll I; Clark JD
    J Addict Med; 2017; 11(5):342-349. PubMed ID: 28514235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ondansetron does not prevent physical dependence in patients taking opioid medications chronically for pain control.
    Chu LF; Rico T; Cornell E; Obasi H; Encisco EM; Vertelney H; Gamble JG; Crawford CW; Sun J; Clemenson A; Erlendson MJ; Okada R; Carroll I; Clark JD
    Drug Alcohol Depend; 2018 Feb; 183():176-183. PubMed ID: 29278818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts.
    Jain K; Jain R; Dhawan A
    J Opioid Manag; 2011; 7(1):11-20. PubMed ID: 21434580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute opioid withdrawal is associated with increased neural activity in reward-processing centers in healthy men: A functional magnetic resonance imaging study.
    Chu LF; Lin JC; Clemenson A; Encisco E; Sun J; Hoang D; Alva H; Erlendson M; Clark JD; Younger JW
    Drug Alcohol Depend; 2015 Aug; 153():314-22. PubMed ID: 26059463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent naloxone-induced morphine withdrawal symptoms in opioid-dependent males-a double-blinded, randomized study.
    Weisshaar S; Brandt L; Litschauer B; Sheik-Rezaei S; Moser L; Nirnberger G; Kühberger E; Bauer U; Firbas C; Gouya G; Wolzt M; Fischer G
    Br J Clin Pharmacol; 2020 Aug; 86(8):1610-1619. PubMed ID: 32145041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abuse deterrence testing: A dose ratio escalation study examining naloxone coadministered with intravenous hydromorphone in non-treatment-seeking, opioid-dependent drug users.
    Levy-Cooperman N; Schoedel KA; Reiz JL; Thompson D; Chakaraborty B; Geoffroy P; Michalko KJ
    J Opioid Manag; 2016; 12(3):165-80. PubMed ID: 27435437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
    Walsh SL; Strain EC; Bigelow GE
    Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of palonosetron versus ramosetron on preventing opioid-based analgesia-related nausea and vomiting after lumbar spinal surgery: a prospective, randomized, and double-blind trial.
    Roh GU; Yang SY; Shim JK; Kwak YL
    Spine (Phila Pa 1976); 2014 Apr; 39(9):E543-9. PubMed ID: 24480956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial.
    Chun HR; Jeon IS; Park SY; Lee SJ; Kang SH; Kim SI
    Br J Anaesth; 2014 Mar; 112(3):485-90. PubMed ID: 24154700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
    Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K
    Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans.
    Bisaga A; Comer SD; Ward AS; Popik P; Kleber HD; Fischman MW
    Psychopharmacology (Berl); 2001 Aug; 157(1):1-10. PubMed ID: 11512037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Ramosetron and Palonosetron for Preventing Nausea and Vomiting after Spinal Surgery: Association With ABCB1 Polymorphisms.
    Song JW; Shim JK; Choi SH; Soh S; Jang J; Kwak YL
    J Neurosurg Anesthesiol; 2017 Oct; 29(4):406-414. PubMed ID: 27564555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers.
    Morganroth J; Flaharty KK; Parisi S; Moresino C
    Support Care Cancer; 2016 Feb; 24(2):621-627. PubMed ID: 26111957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
    Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
    Rehni AK; Bhateja P; Singh TG; Singh N
    Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of palonosetron on the QTc interval in patients undergoing sevoflurane anaesthesia.
    Kim HJ; Lee HC; Jung YS; Lee J; Min JJ; Hong DM; Choi EK; Oh S; Jeon Y
    Br J Anaesth; 2014 Mar; 112(3):460-8. PubMed ID: 24129597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential and additive suppressive effects of 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation.
    Darmani NA; Zhong W; Chebolu S; Mercadante F
    Pharmacol Biochem Behav; 2015 Apr; 131():104-11. PubMed ID: 25687374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
    Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
    Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.